Reactions 1871, p264 - 4 Sep 2021
mRNA-1273 S
Idiopathic thrombocytopenic purpura: case report
A 72-year-old woman developed idiopathic thrombocytopenic purpura following administration of mRNA-1273 Covid-19 vaccine.
The woman received the first dose of the mRNA-1273 vaccine [Moderna COVID-19 vaccine; route and dosage not stated]. On the next day of vaccination, she woke up with spontaneous oral bleeding, rash and headache. No history of abnormal bleeding or easy bruising was reported. She had a history of seasonal contact dermatitis, type II diabetes mellitus and gout. No recent use of new medications was reported. Concomitantly, she had been receiving allopurinol and sitagliptin. No family history of autoimmune disorders was reported. On admission, diffuse petechiae on her legs, arms and abdomen with haemorrhagic bullae of the gingival mucosa were observed. Within 12h of arrival, her initial platelet count significantly decreased to 1000 /mL. No other significant laboratory findings were observed.
Hence, the woman was treated with dexamethasone, immune globulin, rituximab and aminocaproic acid. She also received multiple platelet transfusions. However, her platelet count fluctuated between 1000 /mL and 40000 /mL. The non-contrast CT scan of the head showed no signs of intracranial bleeding. Afterwards, her course was complicated by several episodes of melaena. Based on findings, a diagnosis of idiopathic thrombocytopenic purpura due to the mRNA-1273 vaccine was made [outcome not stated].
Julian JA, et al. Idiopathic Thrombocytopenic Purpura and the Moderna Covid-19 Vaccine. Annals of Emergency Medicine 77: 654-656, No. 6, Jun 2021. Available from:
URL: http://doi.org/10.1016/j.annemergmed.2021.02.011 803591972
1
Reactions 4 Sep 2021 No. 1871 0114-9954/21/1871-0001/$14.95 Adis © 2021 Springer Nature Switzerland AG. All rights reserved
